4//SEC Filing
Besthof Robert 4
Accession 0000950142-21-003503
CIK 0001719406other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:04 PM ET
Size
11.3 KB
Accession
0000950142-21-003503
Insider Transaction Report
Form 4
Besthof Robert
Chief Comm. & Patient Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-16$0.20/sh+63,710$12,742→ 63,710 total - Sale
Common Stock
2021-09-15$11.76/sh−40,000$470,400→ 23,710 total - Award
Restricted Stock Units
2021-08-16+36,290→ 36,290 total→ Common Stock (36,290 underlying) - Conversion
Employee Stock Option (Right to buy)
2021-08-16$0.20/sh−100,000$20,000→ 247,200 totalExercise: $0.20Exp: 2026-03-01→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]The options are fully vested.
- [F2]Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.
Documents
Issuer
NRX Pharmaceuticals, Inc.
CIK 0001719406
Entity typeother
Related Parties
1- filerCIK 0001864650
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 4:04 PM ET
- Size
- 11.3 KB